slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 77,701-77,730
Pages 3,679
Rows per page 30
Component
77,701-77,730 of 110,355
02
Includes detailed footnotes regarding funding assumptions and timing.Houlihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem1 hit
03
Includes detailed footnotes regarding assumptions and specific investor commitments.Houlihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem1 hit
04
Includes a red dashed box highlighting the negative cash flow trend in the final weeks.Houlihan Lokey | Investment Banking Pitch Book | 8 slides · Houlihan Lokey
Consulting deck Investment bank Beat · Problem1 hit
05
Includes a dual-axis line chart for historical trends and a table for future projections.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
09
The chart shows quarterly container volume comparisons between 2023 and 2024, with a specific note on sailing frequency impact.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · So What Cascade1 hit
14
Includes specific footnotes regarding debt calculation and post-period tax refund events.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · EvidenceLoop · Pareto Focus1 hit
08
The slide uses a standard pharmaceutical pipeline visualization format.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) and their respective treatment challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a case study (Osimertinib) to validate the proposed strategy for ALK/ROS1 targets.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
11
The chart uses a bar-horizontal format to compare sales figures for specific drugs (Alectinib, Crizotinib) against a group of 'Other' TKIs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market Size1 hit
13
The slide uses a timeline-based framework to map treatment lines (1L, 2L, 3L+) against clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Includes detailed patient enrollment breakdown by dose cohort and trial phase.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
The chart shows NVL-655 pharmacokinetics across five dose cohorts, highlighting that the 150mg dose maintains levels above efficacy thresholds for various ALK mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
Uses a timeline-based framework to contrast current treatment standards with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a visual comparison matrix to highlight the therapeutic advantages of Zidesamtinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (25mg to 125mg QD) for the ARROS-1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data for Zidesamtinib (NVL-520) in ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data from ARROS-1 Phase 1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide uses a comparative framework to contrast the 2L+ (salvage) and 1L (front-line) market opportunities.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
Includes a footnote regarding non-IFRS measures.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Attention1 hit
06
The slide uses a combination of bar charts to illustrate financial performance trends.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Need1 hit
10
Slide 10 of a presentation deck.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
11
The slide uses a hand-drawn aesthetic consistent with the Oatly brand identity.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
13
The chart shows a steady increase in volume across New European and International markets, with a 29% growth callout.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
14
The 'Go Blue' strategy refers to the blue-colored packaging of specific Oatly SKUs.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
15
The slide uses a visual lineup of product packaging to demonstrate portfolio expansion.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The chart uses a waterfall-like grouping to show annual net cash totals for 2021, 2022, and 2023.Yatsen | Results Presentation Deck | 20 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Satisfaction1 hit